Keywords
How to Cite
Abstract
Background: Lorlatinib is the third generation inhibitor of ALK and ROS1 tyrosine kinase has shown activity in patients with crisotinib-refractory ALK-positive NSCLC most of whom had CNS metastases. We report results of the overall and intracranial antitumor activity of patients with crisotinib-refratory ALK-positive NSCLC. Methods: Patients with ALK and ROS1-positive NSCLC who had progressed after crisotinib and at least one regimen of chemotherapy with or without CNS metastases with ECOG PS was 0-2 and adequate organ functions were given lorlatinib 100 mg orally once daily continuously. Primary endpoint -overall and intracranial objective response, secondary endpoint - safety of lorlatinib. Results: Since January 2017 to July 2018 39 patients were enrolled: ALK+- 36, ROS1+ - 3 pts. Median age 49 years. 27 pts had brain metastases. Objective response was achieved in 22 pts (56, 4%) - 3 complete (7,7%) and 19 partial (48,7%) responses. 16 pts (41%) had stabilization as the best response, 1 ALK+ pt progressed...References
Soda M., Choi YL., Enomoto M. Takada S. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer // Nature. - 2007. - Vol. 448(7153). - P. 561-566. - DOI: 10.1038/nature05945
Sahu A., Prabhash K., Noronha V. et al. Crizotinib: A comprehensive review // South Asian J. Cancer. - 2013. -Vol. 2(2). - P. 91-97. - DOI: 10.4103/2278-330X.110506
Costa D.B., Shaw A.T., Ou S.H. et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases // J. Clin. Oncol. - 2015. - Vol. 33(17). - P 1881-1888. - DOI: 10.1200/JCO.2014.59.0539
Лактионов К.К., Реутова Е.В., Саранцева К.А. ALK-позитивный немелкоклеточный рак легкого и методы его лечения: обзор литературы // Фарматека. - 2015. - № 18 (311). - C.76-79.
Лактионов К.К., Реутова Е.В., Ардзинба М.С., Мещерякова Н.А. Таргетная терапия немелкоклеточного рака легкого при реарранжировке ROS1 // Научно-практический журнал для врачей «Медицинский совет». - 2017. - № 6. - С. 51-55.
Gadgeel S.M., Gandhi L., Riely G.J. et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study // Lancet Oncol. - 2014. - Vol. 15(10). - P. 1119-1128. - DOI: 10.1016/S1470-2045(14)70362-6
Shaw A.T., Engelman J.A. Ceritinib in ALK-rearranged non-small-cell lung cancer // N. Engl. J. Med. - 2014. - Vol. 370. - P. 2537-2539.
Gainor J.F., Tan D.S., De Pas T. et al. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib // Clin. Cancer Res. - 2015. - Vol. 21. - P. 2745-2752. - DOI: 10.1158/1078-0432.CCR-14-3009
Duruisseaux M., Besse B., Cadranel J. et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study // Oncotarget. - 2017. - Vol. 8(13). - P. 21903-21917. - DOI: 10.18632/oncotarget.1
Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future // J. Clin. Oncol. - 2013. - Vol. 31(8). - P1105-1111. - doi: 10.1200Д1Ш.2012.44.5353.
Sharma G.G. Mota I., Mologni L. et al. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes // Cancers (Basel). - 2018. - Vol. 10(3). - P E62. - DOI: 10.3390/cancers10030062
Solomon B.J., Besse B., Bauer T.M. et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study // Lancet Oncol. - 2018. - Vol. 19(12). - P. 1654-1667. - DOI: 10.1016/S1470-2045
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019